Cargando…

Dual versus monotherapy with bronchodilators in GOLD group B COPD patients according to baseline FEV(1) level: a patient-level pooled analysis of phase-3 randomized clinical trials

BACKGROUND: Which patients should receive dual therapy as initial treatment for chronic obstructive pulmonary disease (COPD) is only loosely defined. We evaluated if a lower forced expiratory volume in 1 s (FEV(1)) identifies a population more likely to benefit from dual therapy than monotherapy amo...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kang, Jieun, Lee, Jae Seung, Lee, Sei Won, Lee, Jung Bok, Oh, Yeon-Mok
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7881547/ https://www.ncbi.nlm.nih.gov/pubmed/33579288 http://dx.doi.org/10.1186/s12931-021-01648-5

Ejemplares similares

COPD exacerbations and patient-reported outcomes according to post-bronchodilator FEV(1) – a post-hoc analysis of pooled data
por: Chai, Chee-Shee, et al.
Publicado: (2023)

Bronchodilator Response of FEV6 and FEV3 as Surrogates of Forced Vital Capacity
por: Mehrparvar, Amir Houshang, et al.
Publicado: (2014)

Patient-reported outcomes of dual bronchodilator fixed-dose combination versus bronchodilator monotherapy in individuals with COPD
por: Strange, Charlie, et al.
Publicado: (2019)

Future concepts in bronchodilation for COPD: dual- versus monotherapy
por: Singh, Dave, et al.
Publicado: (2021)

Predicting treatable traits for long-acting bronchodilators in patients with stable COPD
por: Kang, Jieun, et al.
Publicado: (2017)

Relationship between FEV(1 )change and patient-reported outcomes in randomised trials of inhaled bronchodilators for stable COPD: a systematic review
por: Westwood, Marie, et al.
Publicado: (2011)

Bronchodilators use in patients with COPD
por: Dong, Yaa-Hui, et al.
Publicado: (2015)

Responses of FEV(6), FVC, and FET to inhaled bronchodilator in the adult general population
por: Kainu, Annette, et al.
Publicado: (2009)

A reply to questions raised about FEV(1)Q and bronchodilator responsiveness
por: Miller, Martin R., et al.
Publicado: (2023)

Effects of long-term bronchodilators in bronchiectasis patients with airflow limitation based on bronchodilator response at baseline
por: Jeong, Ho Jung, et al.
Publicado: (2016)

Which bronchodilator in COPD?
por: Russell, Richard, et al.
Publicado: (2007)

COPD: maximization of bronchodilation
por: Nardini, Stefano, et al.
Publicado: (2014)

A Pooled Analysis of Mortality in Patients with COPD Receiving Dual Bronchodilation with and without Additional Inhaled Corticosteroid
por: Miravitlles, Marc, et al.
Publicado: (2022)

A novel CT-emphysema index/FEV(1) approach of phenotyping COPD to predict mortality
por: Loh, Li-Cher, et al.
Publicado: (2018)

Flow and volume response to bronchodilator in patients with COPD
por: Matteo, Vigna, et al.
Publicado: (2018)

Isolation of filamentous fungi from sputum in asthma is associated with reduced post-bronchodilator FEV(1)
por: Agbetile, J, et al.
Publicado: (2012)

Bronchodilator response cut-off points and FEV (0.75) reference values for spirometry in preschoolers
por: Burity, Edjane Figueiredo, et al.
Publicado: (2016)

Comparison of the variability of the annual rates of change in FEV(1) determined from serial measurements of the pre- versus post-bronchodilator FEV(1) over 5 years in mild to moderate COPD: Results of the lung health study
por: Tashkin, Donald P, et al.
Publicado: (2012)

Lower FEV(1) in non-COPD, nonasthmatic subjects: association with smoking, annual decline in FEV(1), total IgE levels, and TSLP genotypes
por: Masuko, Hironori, et al.
Publicado: (2011)

Diagnostic accuracy of pre-bronchodilator FEV(1)/FEV(6) from microspirometry to detect airflow obstruction in primary care: a randomised cross-sectional study
por: van den Bemt, Lisette, et al.
Publicado: (2014)

Bronchodilator efficacy and safety of indacaterol 150 μg once daily in patients with COPD: an analysis of pooled data
por: Bleecker, Eugene R, et al.
Publicado: (2011)

Indacaterol/glycopyrronium versus tiotropium or glycopyrronium in long‐acting bronchodilator‐naïve COPD patients: A pooled analysis
por: Muro, Shigeo, et al.
Publicado: (2019)

Association Between Vitamin D Levels and FEV1, Number of Exacerbations, and CAT Score in Stable COPD Patients in Indonesia
por: Soeroto, Arto Yuwono, et al.
Publicado: (2021)

Serum C-reactive protein level in COPD patients stratified according to GOLD 2011 grading classification
por: Lin, Yi-Hua, et al.
Publicado: (2016)

Inflammatory and immunological profiles in patients with COPD: relationship with FEV (1) reversibility
por: Queiroz, Cleriston Farias, et al.
Publicado: (2016)

Low FEV1 Is Associated With Increased Risk Of Cachexia In COPD Patients
por: Mokari-Yamchi, Amin, et al.
Publicado: (2019)

Optimizing bronchodilation in the prevention of COPD exacerbations
por: Miravitlles, Marc, et al.
Publicado: (2017)

When is dual bronchodilation indicated in COPD?
por: Thomas, Mike, et al.
Publicado: (2017)

Diagnosis, assessment, and phenotyping of COPD: beyond FEV(1)
por: Lange, Peter, et al.
Publicado: (2016)

Adherence to roflumilast under dose-escalation strategy in Korean patients with COPD
por: Park, Tai Sun, et al.
Publicado: (2019)

Airway wall thickness is increased in COPD patients with bronchodilator responsiveness
por: Kim, Victor, et al.
Publicado: (2014)

Bronchodilator reversibility in patients with COPD revisited: short-term reproducibility
por: Pascoe, Steven, et al.
Publicado: (2016)

Spirometry and Bronchodilator Test
por: Sim, Yun Su, et al.
Publicado: (2017)

Impact of baseline COPD symptom severity on the benefit from dual versus mono-bronchodilators: an analysis of the EMAX randomised controlled trial
por: Vogelmeier, Claus F., et al.
Publicado: (2020)

Beyond FEV(1) in COPD: a review of patient-reported outcomes and their measurement
por: Jones, Paul, et al.
Publicado: (2012)

COPD assessment test and FEV(1): do they predict oxygen uptake in COPD?
por: Carvalho-Jr, Luiz Carlos S, et al.
Publicado: (2018)

Establishing Quality of Life in Southern Taiwan COPD Patients Using Long-Acting Bronchodilator
por: Chin, Pik-Qi, et al.
Publicado: (2022)

Impact of bronchodilator therapy on exercise tolerance in COPD
por: Aguilaniu, B
Publicado: (2010)

The role of bronchodilator treatment in the prevention of exacerbations of COPD
por: Wedzicha, Jadwiga A., et al.
Publicado: (2012)

Acute bronchodilator responsiveness and health outcomes in COPD patients in the UPLIFT trial
por: Hanania, Nicola A, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_4p7b46pcmo3ag5f45h7tnns39u